Skip to Content

Soliqua 100/33 Approval History

FDA Approved: Yes (First approved November 21, 2016)
Brand name: Soliqua 100/33
Generic name: insulin glargine and lixisenatide
Dosage form: Injection
Company: Sanofi
Treatment for: Diabetes, Type 2

Soliqua 100/33 (insulin glargine and lixisenatide) is fixed-ratio combination of the long-acting human insulin analog insulin glargine (Lantus) and the glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Development History and FDA Approval Process for Soliqua 100/33

DateArticle
Feb 27, 2019Approval FDA Expands Indication for Soliqua 100/33 (insulin glargine and lixisenatide injection) to Include Type 2 Diabetes Patients Uncontrolled on Oral Antidiabetic Medicines
Nov 21, 2016Approval Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes
Aug 20, 2016Zealand Announces New Timelines for a U.S. FDA Decision on iGlarLixi, the Fixed-Ratio Combination of Lixisenatide (Adlyxin) and Lantus, for the Treatment of Type 2 Diabetes
May 25, 2016FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults With Type 2 Diabetes
Feb 22, 2016FDA Accepts Sanofi NDA for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
Dec 23, 2015Sanofi Submits NDA for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
Jul 29, 2015Sanofi Announces That First LixiLan Phase III Study Met Primary Endpoint

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide